Contents

Ameet Nathwani at Dewpoint Therapeutics considers the use of biomolecular condensates as a potential treatment option
Alexander Gebauer from Galimedix Therapeutics explains the link between AD and AMD and how treatment for both could develop in the future
Betsy Goodfellow from Pharmafocus considers the impact of the ongoing cost of living crisis and why this is so significant in terms of health

Top News

Page 4Report finds NHS may miss out on new drugs due to rising costs
Page 6AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
Page 7– SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy
Page 8FDA approves Pfizer’s RSV vaccine for older adults
Page 10Scientists at MIT and McMaster University use AI to find new antibiotic to fight superbug
Page 12Astellas and Sony enter collaborative research agreement

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com

James Spargo
james@samedanltd.com
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2023 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.